Summary
Global Markets Direct’s, ‘Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2016’, provides an overview of the Post-Traumatic Stress Disorder (PTSD) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Post-Traumatic Stress Disorder (PTSD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Post-Traumatic Stress Disorder (PTSD) and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Post-Traumatic Stress Disorder (PTSD)
- The report reviews pipeline therapeutics for Post-Traumatic Stress Disorder (PTSD) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Post-Traumatic Stress Disorder (PTSD) therapeutics and enlists all their major and minor projects
- The report assesses Post-Traumatic Stress Disorder (PTSD) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Post-Traumatic Stress Disorder (PTSD)
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Post-Traumatic Stress Disorder (PTSD)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Post-Traumatic Stress Disorder (PTSD) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Addex Therapeutics Ltd
Amorsa Therapeutics Inc.
Azevan Pharmaceuticals, Inc.
Bionomics Limited
Catalyst Pharmaceuticals, Inc.
Eli Lilly and Company
Humanetics Corporation
Intra-Cellular Therapies, Inc.
INVENT Pharmaceuticals, Inc.
Marinus Pharmaceuticals,
'
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Post-Traumatic Stress Disorder (PTSD) Overview 10
Therapeutics Development 11
Pipeline Products for Post-Traumatic Stress Disorder (PTSD) - Overview 11
Pipeline Products for Post-Traumatic Stress Disorder (PTSD) - Comparative Analysis 12
Post-Traumatic Stress Disorder (PTSD) - Therapeutics under Development by Companies 13
Post-Traumatic Stress Disorder (PTSD) - Therapeutics under Investigation by Universities/Institutes 15
Post-Traumatic Stress Disorder (PTSD) - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Unknown Stage Products 19
Post-Traumatic Stress Disorder (PTSD) - Products under Development by Companies 20
Post-Traumatic Stress Disorder (PTSD) - Products under Investigation by Universities/Institutes 22
Post-Traumatic Stress Disorder (PTSD) - Companies Involved in Therapeutics Development 23
Addex Therapeutics Ltd 23
Amorsa Therapeutics Inc. 24
Azevan Pharmaceuticals, Inc. 25
Bionomics Limited 26
Catalyst Pharmaceuticals, Inc. 27
Eli Lilly and Company 28
Humanetics Corporation 29
Intra-Cellular Therapies, Inc. 30
INVENT Pharmaceuticals, Inc. 31
Marinus Pharmaceuticals, Inc. 32
Neuralstem, Inc. 33
NeuroNascent, Inc. 34
Omeros Corporation 35
Otsuka Holdings Co., Ltd. 36
Polleo Pharma Limited 37
Pragma Therapeutics 38
Synchroneuron Inc. 39
Tonix Pharmaceuticals Holding Corp. 40
TRImaran Pharma, Inc. 41
Turing Pharmaceuticals AG 42
Post-Traumatic Stress Disorder (PTSD) - Therapeutics Assessment 43
Assessment by Monotherapy Products 43
Assessment by Target 44
Assessment by Mechanism of Action 47
Assessment by Route of Administration 50
Assessment by Molecule Type 52
Drug Profiles 54
acamprosate calcium SR - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
ADX-71743 - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
AM-3506 - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
BNC-210 - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
brexpiprazole - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
CPP-115 - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
D-473 - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
ganaxolone - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
HL-9001 - Drug Profile 77
Product Description 77
Mechanism Of Action 77
R&D Progress 77
IC-87201 - Drug Profile 78
Product Description 78
Mechanism Of Action 78
R&D Progress 78
INV-107 - Drug Profile 79
Product Description 79
Mechanism Of Action 79
R&D Progress 79
INV-170 - Drug Profile 80
Product Description 80
Mechanism Of Action 80
R&D Progress 80
ITI-007 - Drug Profile 81
Product Description 81
Mechanism Of Action 81
R&D Progress 81
KDAC-0001 - Drug Profile 89
Product Description 89
Mechanism Of Action 89
R&D Progress 89
ketamine hydrochloride - Drug Profile 90
Product Description 90
Mechanism Of Action 90
R&D Progress 90
modafinil - Drug Profile 91
Product Description 91
Mechanism Of Action 91
R&D Progress 91
NNI-351 - Drug Profile 92
Product Description 92
Mechanism Of Action 92
R&D Progress 92
NSI-189 - Drug Profile 93
Product Description 93
Mechanism Of Action 93
R&D Progress 93
PGT-117 - Drug Profile 97
Product Description 97
Mechanism Of Action 97
R&D Progress 97
Rycal - Drug Profile 98
Product Description 98
Mechanism Of Action 98
R&D Progress 98
S-107 - Drug Profile 99
Product Description 99
Mechanism Of Action 99
R&D Progress 99
Small Molecule to Activate TrkB Receptor for Central Nervous System, Metabolic Disorders and ENT Disorders - Drug Profile 100
Product Description 100
Mechanism Of Action 100
R&D Progress 100
Small Molecule to Target GPR151 for CNS Diseases - Drug Profile 101
Product Description 101
Mechanism Of Action 101
R&D Progress 101
Small Molecule to Target GPR83 for CNS and Immunological Disorders - Drug Profile 102
Product Description 102
Mechanism Of Action 102
R&D Progress 102
Small Molecules for Post-Traumatic Stress Disorder - Drug Profile 103
Product Description 103
Mechanism Of Action 103
R&D Progress 103
Small Molecules to Antagonize mGluR7 For Central Nervous System Disorders - Drug Profile 104
Product Description 104
Mechanism Of Action 104
R&D Progress 104
Small Molecules to Antagonize TLR-4 for CNS Disorders - Drug Profile 105
Product Description 105
Mechanism Of Action 105
R&D Progress 105
Small Molecules to Target NMDA Receptor for Post-Traumatic Stress Disorder - Drug Profile 106
Product Description 106
Mechanism Of Action 106
R&D Progress 106
SRX-246 - Drug Profile 107
Product Description 107
Mechanism Of Action 107
R&D Progress 107
Synthetic Peptide to Antagonize EPHA4 for Post-Traumatic Stress Disorder - Drug Profile 109
Product Description 109
Mechanism Of Action 109
R&D Progress 109
TNX-102 - Drug Profile 110
Product Description 110
Mechanism Of Action 110
R&D Progress 110
URB-694 - Drug Profile 119
Product Description 119
Mechanism Of Action 119
R&D Progress 119
Vaccine for CNS Disorders - Drug Profile 120
Product Description 120
Mechanism Of Action 120
R&D Progress 120
ZL-006 - Drug Profile 121
Product Description 121
Mechanism Of Action 121
R&D Progress 121
Post-Traumatic Stress Disorder (PTSD) - Dormant Projects 122
Post-Traumatic Stress Disorder (PTSD) - Discontinued Products 124
Post-Traumatic Stress Disorder (PTSD) - Product Development Milestones 125
Featured News & Press Releases 125
Jun 30, 2016: Bionomics To Trial Drug Against Post-Traumatic Stress Disorder 125
Jun 13, 2016: Addex mGluR7 Program Demonstrate Potential in Preclinical Models of Neurodegenerative and Psychiatric Diseases 125
Jun 03, 2016: Tonix Pharmaceuticals to Present at the 2016 BIO International Convention 126
May 31, 2016: Tonix Pharmaceuticals Presents Positive Results from Phase 2 AtEase Study of TNX-102 SL in Post-Traumatic Stress Disorder at the American Society of Clinical Psychopharmacology 2016 Annual Meeting 126
May 26, 2016: Tonix Pharmaceuticals to Present Positive Results from Phase 2 AtEase Study of TNX-102 SL in Post-Traumatic Stress Disorder at the ASCP 2016 Annual Meeting 127
May 19, 2016: Tonix Pharmaceuticals Reports Positive Topline Results from Phase 2 AtEase Study of TNX-102 SL in Post-Traumatic Stress Disorder (PTSD) 128
Mar 09, 2016: Tonix Pharmaceuticals Presents Pharmacokinetic Data on TNX-102 SL as a Potential Treatment for the Management of Fibromyalgia and Treatment of Post-Traumatic Stress Disorder at the ASCPT 2016 Annual Meeting 129
Dec 23, 2015: Tonix Pharmaceuticals Completes Enrollment in Phase 2 Clinical Trial of TNX-102 SL in Post-Traumatic Stress Disorder 130
Dec 08, 2015: Post Traumatic Stress Disorder Identified as Major New Market Opportunity for BNC210 130
Nov 23, 2015: The SEVEN4PTSD consortium led by PRAGMA Therapeutics awarded 2015 French ANR grant to further advance its mGlu7 program for Post-Traumatic Stress Disorder 131
Oct 29, 2015: Marinus Announces Clinical Development Plans for Ganaxolone Intravenous Formulation 132
Aug 18, 2015: Tonix Pharmaceuticals Presents on the Development of TNX-102 SL for Post-Traumatic Stress Disorder (PTSD) at the 2015 Military Health System Research Symposium 133
May 26, 2015: Tonix Pharmaceuticals Announces Acceptance of Two Abstracts for Presentation at EULAR 134
May 15, 2015: Tonix Pharmaceuticals Presents Data at the Annual Meeting of the Society for Biological Psychiatry 134
Jan 15, 2015: Tonix Pharmaceuticals Commences Phase 2 Trial of TNX-102 SL in Post-Traumatic Stress Disorder 134
Appendix 136
Methodology 136
Coverage 136
Secondary Research 136
Primary Research 136
Expert Panel Validation 136
Contact Us 136
Disclaimer 137
List of Tables
Number of Products under Development for Post-Traumatic Stress Disorder (PTSD), H2 2016 11
Number of Products under Development for Post-Traumatic Stress Disorder (PTSD) - Comparative Analysis, H2 2016 12
Number of Products under Development by Companies, H2 2016 14
Number of Products under Investigation by Universities/Institutes, H2 2016 15
Comparative Analysis by Late Stage Development, H2 2016 16
Comparative Analysis by Clinical Stage Development, H2 2016 17
Comparative Analysis by Early Stage Development, H2 2016 18
Comparative Analysis by Unknown Stage Development, H2 2016 19
Products under Development by Companies, H2 2016 20
Products under Development by Companies, H2 2016 (Contd..1) 21
Products under Investigation by Universities/Institutes, H2 2016 22
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Addex Therapeutics Ltd, H2 2016 23
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Amorsa Therapeutics Inc., H2 2016 24
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Azevan Pharmaceuticals, Inc., H2 2016 25
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Bionomics Limited, H2 2016 26
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Catalyst Pharmaceuticals, Inc., H2 2016 27
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Eli Lilly and Company, H2 2016 28
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Humanetics Corporation, H2 2016 29
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Intra-Cellular Therapies, Inc., H2 2016 30
Post-Traumatic Stress Disorder (PTSD) - Pipeline by INVENT Pharmaceuticals, Inc., H2 2016 31
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Marinus Pharmaceuticals, Inc., H2 2016 32
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Neuralstem, Inc., H2 2016 33
Post-Traumatic Stress Disorder (PTSD) - Pipeline by NeuroNascent, Inc., H2 2016 34
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Omeros Corporation, H2 2016 35
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Otsuka Holdings Co., Ltd., H2 2016 36
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Polleo Pharma Limited, H2 2016 37
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Pragma Therapeutics, H2 2016 38
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Synchroneuron Inc., H2 2016 39
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Tonix Pharmaceuticals Holding Corp., H2 2016 40
Post-Traumatic Stress Disorder (PTSD) - Pipeline by TRImaran Pharma, Inc., H2 2016 41
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Turing Pharmaceuticals AG , H2 2016 42
Assessment by Monotherapy Products, H2 2016 43
Number of Products by Stage and Target, H2 2016 45
Number of Products by Stage and Mechanism of Action, H2 2016 48
Number of Products by Stage and Route of Administration, H2 2016 51
Number of Products by Stage and Molecule Type, H2 2016 53
Post-Traumatic Stress Disorder (PTSD) - Dormant Projects, H2 2016 122
Post-Traumatic Stress Disorder (PTSD) - Dormant Projects (Contd..1), H2 2016 123
Post-Traumatic Stress Disorder (PTSD) - Discontinued Products, H2 2016 124
List of Figures
Number of Products under Development for Post-Traumatic Stress Disorder (PTSD), H2 2016 11
Number of Products under Development for Post-Traumatic Stress Disorder (PTSD) - Comparative Analysis, H2 2016 12
Number of Products under Development by Companies, H2 2016 13
Number of Products under Investigation by Universities/Institutes, H2 2016 15
Comparative Analysis by Clinical Stage Development, H2 2016 17
Comparative Analysis by Early Stage Products, H2 2016 18
Assessment by Monotherapy Products, H2 2016 43
Number of Products by Top 10 Targets, H2 2016 44
Number of Products by Stage and Top 10 Targets, H2 2016 44
Number of Products by Top 10 Mechanism of Actions, H2 2016 47
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 47
Number of Products by Routes of Administration, H2 2016 50
Number of Products by Stage and Routes of Administration, H2 2016 50
Number of Products by Molecule Types, H2 2016 52
Number of Products by Stage and Molecule Types, H2 2016 52
